BNP/PUT/ELI LILLY & CO/900/0.1/20.06.25 | Market Closed - Boerse Frankfurt Warrants 20:50:32 03/07/2024 BST | ||
| 9.31 EUR | +4.49% |
|
| Current month | +6.99% | ||
| 1 month | -22.75% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 03/07/24 | 9.34 | +4.83% |
| 02/07/24 | 8.91 | +4.45% |
| 01/07/24 | 8.53 | -2.29% |
| 28/06/24 | 8.73 | -0.46% |
| 27/06/24 | 8.77 | -2.56% |
Real-time Boerse Frankfurt Warrants
Last update July 03, 2024 at 08:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
BNP Paribas
|
| WKN | PC9XJH |
| ISIN | DE000PC9XJH7 |
| Date issued | 15/05/2024 |
| Strike | 900 $ |
| Maturity | 20/06/2025 (352 Days) |
| Parity | 10 : 1 |
| Emission price | 13.58 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 15.55 € |
|---|---|
| Lowest since issue | 8.37 € |
| Spread | 0.11 € |
| Spread % | 1.17% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
898.1
USD
Average target price
870.3
USD
Spread / Average Target
-3.10%
- Stock Market
- Warrants
- Warrant
